Profiling the Use of Complementary Alternative Medicines among Inflammatory Bowel Disease Patients: Results from a Single Center Survey

Padhmanand Sudhakar(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Bep Keersmaekers(KU Leuven), Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), A Paps(KU Leuven), João Sabino(KU Leuven), Judith Wellens(KU Leuven), Tessy Lambrechts(KU Leuven), Rita Stiers(KU Leuven), Patricia Geens(KU Leuven), Els De Dycker(KU Leuven)
GastroHep
July 22, 2022
10.1155/2022/9919542
Cited by 5

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k